FBR Remains Positive on Genocea Biosciences (GNCA) Following ATLAS Update; Affirms at 'Outperform'
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Genocea’s Proprietary ATLAS™ Technology Identifies Unique Candidate Antigens for Potential Personalized Cancer Vaccines
November 11, 2016 7:00 AM EST- ATLAS discovers neoantigens, through functional T cell responses, which were not identified by predictive algorithms -
- Majority of antigens predicted by algorithms not biologically relevant in ATLAS assays -
- Data to be presented at 2016 SITC Annual Meeting -
CAMBRIDGE, Mass., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented new findings supporting the potential of ATLASTM, the Companys proprietary rapid antigen identification screening system, to identify clinically meaningful... More